A head-to-head trial would be the cleanest way to compare two medicines under the same rules
Chang AM, Jakobsen G, Sturis J, et al
Generally, GLP-1 agonist medications are FDA approved for adults aged 18 years and older with certain body mass indexes (BMI) (typically a BMI of 30 or above, or a BMI of 27 or above if you have a weight-related health condition such as hypertension, high cholesterol, weight-related anxiety, liver disease, sleep apnea or PCOS)
GLP-1 RA use was consistently associated with improvements in headache frequency, weight reduction, and reduced need for acetazolamide or surgical interventions
In addition to GLP-1/GIP/GCG receptors tri-agonists, there are also triagonists targeting Xenopus GLP-1/GCG/Cholecystokinin-2 (CCK2) receptors [107], GLP-1/GCG/ neuropeptide Y 2 receptors [108], and GLP-1R, neuropeptide Y1, and neuropeptide Y2 receptors [109]
Women Over 40 and Perimenopausal Perimenopause introduces fluctuating estrogen levels that can make the Retatrutide response less predictable month to month
